- Home
- AMBO vs POAI Comparison
AMBO vs POAI Comparison
Compare AMBO & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- POAI
- Stock Information
- Founded
- AMBO 2000
- POAI 2002
- Country
- AMBO United States
- POAI United States
- Employees
- AMBO N/A
- POAI N/A
- Industry
- AMBO Other Consumer Services
- POAI Industrial Specialties
- Sector
- AMBO Real Estate
- POAI Health Care
- Exchange
- AMBO Nasdaq
- POAI Nasdaq
- Market Cap
- AMBO 5.1M
- POAI 4.9M
- IPO Year
- AMBO 2010
- POAI N/A
- Fundamental
- Price
- AMBO $1.42
- POAI $0.67
- Analyst Decision
- AMBO
- POAI Hold
- Analyst Count
- AMBO 0
- POAI 1
- Target Price
- AMBO N/A
- POAI N/A
- AVG Volume (30 Days)
- AMBO 157.1K
- POAI 93.4K
- Earning Date
- AMBO 12-27-2024
- POAI 11-12-2024
- Dividend Yield
- AMBO N/A
- POAI N/A
- EPS Growth
- AMBO N/A
- POAI N/A
- EPS
- AMBO N/A
- POAI N/A
- Revenue
- AMBO $9,163,000.00
- POAI $1,484,223.00
- Revenue This Year
- AMBO N/A
- POAI N/A
- Revenue Next Year
- AMBO N/A
- POAI $569.48
- P/E Ratio
- AMBO N/A
- POAI N/A
- Revenue Growth
- AMBO N/A
- POAI N/A
- 52 Week Low
- AMBO $1.00
- POAI $0.55
- 52 Week High
- AMBO $6.30
- POAI $3.76
- Technical
- Relative Strength Index (RSI)
- AMBO 40.93
- POAI 40.28
- Support Level
- AMBO $1.35
- POAI $0.69
- Resistance Level
- AMBO $1.56
- POAI $0.76
- Average True Range (ATR)
- AMBO 0.18
- POAI 0.06
- MACD
- AMBO -0.05
- POAI -0.01
- Stochastic Oscillator
- AMBO 7.55
- POAI 2.95
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.